Toyoda Hidenori, Fujii Hideki, Iwaki Michihiro, Hayashi Hideki, Oeda Satoshi, Hyogo Hideyuki, Kawanaka Miwa, Morishita Asahiro, Munekage Kensuke, Kawata Kazuhito, Yamamura Sakura, Sawada Koji, Maeshiro Tatsuji, Tobita Hiroshi, Yoshida Yuichi, Naito Masafumi, Araki Asuka, Arakaki Shingo, Kawaguchi Takumi, Noritake Hidenao, Ono Masafumi, Masaki Tsutomu, Yasuda Satoshi, Tomita Eiichi, Yoneda Masato, Kawada Norifumi, Tokushige Akihiro, Kamada Yoshihiro, Takahashi Hirokazu, Ueda Shinichiro, Aishima Shinichi, Sumida Yoshio, Nakajima Atsushi, Okanoue Takeshi
Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.
Departments of Premier Preventive Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Gastro Hep Adv. 2023 Aug 2;2(8):1093-1102. doi: 10.1016/j.gastha.2023.07.018. eCollection 2023.
Nonalcoholic fatty liver diseases (NAFLD) and nonalcoholic steatohepatitis (NASH) can cause hepatocellular carcinoma (HCC). We examined histological features and reported noninvasive markers/models for stratifying the risk of HCC development in patients with biopsy-proven NAFLD or NASH.
A total of 1389 patients who had a histological diagnosis of NAFLD or NASH based on liver biopsy and underwent regular surveillance for HCC were included. The ability to predict HCC development was compared between histological features including liver fibrosis and NAFLD activity score, and noninvasive markers/models including aMAP (age, male, albumin-bilirubin, and platelet) score, FIB-4 (Fibrosis-4) index, and ALBI (albumin-bilirubin) score calculated at the time of biopsy.
The C index of aMAP score was 0.887, which was consistent with the original report, comparable to FIB-4 index (0.878), and higher than those of ALBI score (0.789), histological liver fibrosis (0.723), and NAFLD activity score (0.589). The hazard ratios for HCC development in the aMAP intermediate and high-risk groups were 21.0 (95% confidence interval [CI], 3.6-402.0) and 110.3 (95% CI, 16.3-2251.4), respectively, in comparison to the aMAP score low-risk group. Those in the FIB-4 index moderate- and high-fibrosis groups were 10.3 (95% CI, 1.7-199.8) and 93.1 (95% CI, 16.3-1773.8), respectively, in comparison to the FIB-4 index mild-fibrosis group. No patients in the aMAP score low-risk group developed HCC during the study period.
For stratifying the risk of HCC development in patients with biopsy-proven NAFLD or NASH, both aMAP score and FIB-4 index showed high discriminative ability as noninvasive markers, which were superior histological features.
非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)可导致肝细胞癌(HCC)。我们研究了组织学特征,并报告了用于对经活检证实的NAFLD或NASH患者发生HCC的风险进行分层的非侵入性标志物/模型。
总共纳入了1389例经肝活检组织学诊断为NAFLD或NASH并接受HCC定期监测的患者。比较了包括肝纤维化和NAFLD活动评分在内的组织学特征,以及包括aMAP(年龄、男性、白蛋白-胆红素和血小板)评分、FIB-4(纤维化-4)指数和活检时计算的ALBI(白蛋白-胆红素)评分在内的非侵入性标志物/模型预测HCC发生的能力。
aMAP评分的C指数为0.887,与原始报告一致,与FIB-4指数(0.878)相当,高于ALBI评分(0.789)、组织学肝纤维化(0.723)和NAFLD活动评分(0.589)。与aMAP评分低风险组相比,aMAP中风险组和高风险组发生HCC的风险比分别为21.0(95%置信区间[CI],3.6 - 402.0)和110.3(95%CI,16.3 - 2251.4)。与FIB-4指数轻度纤维化组相比,FIB-4指数中度和高度纤维化组的风险比分别为10.3(95%CI,1.7 - 199.8)和93.1(95%CI,16.3 - 1773.8)。在研究期间,aMAP评分低风险组没有患者发生HCC。
对于经活检证实的NAFLD或NASH患者发生HCC的风险分层,aMAP评分和FIB-4指数作为非侵入性标志物均显示出较高的鉴别能力,优于组织学特征。